Stocks / MBOT
Microbot Medical Inc.'s 10-K, read.
Bob rates Microbot Medical Inc. (MBOT) 28/100, bearish, on the 10-K filed March 26, 2026, updated through the 10-Q filed August 11, 2026.
Microbot Medical is a pre-revenue medical device company with FDA 510(k) clearance for LIBERTY (September 2025) and limited market release underway, but faces existential cash burn, massive dilution, zero commercial traction to date, and critical dependence on a single unproven product in a competitive space dominated by well-capitalized rivals.
- Zero revenue through December 31, 2025 with significant accumulated operating losses; company expects continued substantial losses and has not demonstrated path to profitability
- Acute cash burn and capital needs; company relies entirely on continuous equity financing (multiple Series of preferred stock placements in 2025, ATM offering program) with extreme dilution risk to existing shareholders
- LIBERTY is sole commercial product; limited market release announced November 2025 with only two hospitals (Emory, Tampa General) publicly identified; full market release planned April 2026 with no revenue visibility or adoption commitments
- Intense competition from CorPath GRX (Siemens Healthineers), Robocath R-One+, and emerging competitors; competitors have significantly greater resources, established healthcare relationships, GPO contracts, and distributor networks
- No reimbursement strategy or payer coverage secured; third-party reimbursement is critical to commercial viability and remains unresolved
Not investment advice — general research, the same for every reader. You make your own calls.
Want the full read?
Run MBOT in Bob for the live meter, or go deep with five years of filings behind it.
Read MBOT in Bob →Last read October 22, 2026. Bob's Research is a financial publisher, not an investment adviser. Everything here is general research and education — not personalized advice, and not a recommendation to buy or sell any security. Ratings are the same for every reader. You make your own calls.